These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 11895892)

  • 1. Histone deacetylase inhibitors: a new class of potential therapeutic agents for cancer treatment.
    Richon VM; O'Brien JP
    Clin Cancer Res; 2002 Mar; 8(3):662-4. PubMed ID: 11895892
    [No Abstract]   [Full Text] [Related]  

  • 2. Inhibition of histone deacetylases: a new strategy to target epigenetic modifications for anticancer treatment.
    Weidle UH; Grossmann A
    Anticancer Res; 2000; 20(3A):1471-85. PubMed ID: 10928059
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Histone deacetylase inhibitors--new anticancer agents?].
    Yoshida M; Horinouchi S
    Tanpakushitsu Kakusan Koso; 2000 Apr; 45(6 Suppl):1090-5. PubMed ID: 10771678
    [No Abstract]   [Full Text] [Related]  

  • 4. Histone deacetylase inhibitors and demethylating agents: clinical development of histone deacetylase inhibitors for cancer therapy.
    Piekarz RL; Sackett DL; Bates SE
    Cancer J; 2007; 13(1):30-9. PubMed ID: 17464244
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Histone deacetylase inhibitors in cancer therapy.
    Fouladi M
    Cancer Invest; 2006; 24(5):521-7. PubMed ID: 16939962
    [No Abstract]   [Full Text] [Related]  

  • 6. [[Inhibitors of histone deacetylase as new agents for prevention and treatment of cancer] ].
    Jung M
    Pharm Unserer Zeit; 2000 Nov; 29(6):385-8. PubMed ID: 11199916
    [No Abstract]   [Full Text] [Related]  

  • 7. FR-901228 Fujisawa/National Cancer Institute.
    Vigushin DM
    Curr Opin Investig Drugs; 2002 Sep; 3(9):1396-402. PubMed ID: 12498018
    [TBL] [Abstract][Full Text] [Related]  

  • 8. FK228 (depsipeptide): a HDAC inhibitor with pleiotropic antitumor activities.
    Konstantinopoulos PA; Vandoros GP; Papavassiliou AG
    Cancer Chemother Pharmacol; 2006 Nov; 58(5):711-5. PubMed ID: 16435156
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Histone deacetylation in epigenetics: an attractive target for anticancer therapy.
    Mai A; Massa S; Rotili D; Cerbara I; Valente S; Pezzi R; Simeoni S; Ragno R
    Med Res Rev; 2005 May; 25(3):261-309. PubMed ID: 15717297
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Histone deacetylase inhibitors.
    Kelly WK
    Clin Adv Hematol Oncol; 2004 Nov; 2(11):722-3. PubMed ID: 16163258
    [No Abstract]   [Full Text] [Related]  

  • 11. Role of histone deacetylase inhibitors in the treatment of cancer (Review).
    Mei S; Ho AD; Mahlknecht U
    Int J Oncol; 2004 Dec; 25(6):1509-19. PubMed ID: 15547685
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical studies of histone deacetylase inhibitors.
    Prince HM; Bishton MJ; Harrison SJ
    Clin Cancer Res; 2009 Jun; 15(12):3958-69. PubMed ID: 19509172
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Histone deacetylase inhibitors: overview and perspectives.
    Dokmanovic M; Clarke C; Marks PA
    Mol Cancer Res; 2007 Oct; 5(10):981-9. PubMed ID: 17951399
    [TBL] [Abstract][Full Text] [Related]  

  • 14. HDAC inhibitors: a potential new category of anti-tumor agents.
    Pan LN; Lu J; Huang B
    Cell Mol Immunol; 2007 Oct; 4(5):337-43. PubMed ID: 17976313
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A novel combination of suicide gene therapy and histone deacetylase inhibitor for treatment of malignant melanoma.
    Yamamoto S; Yamano T; Tanaka M; Hoon DS; Takao S; Morishita R; Aikou T; Kaneda Y
    Cancer Gene Ther; 2003 Mar; 10(3):179-86. PubMed ID: 12637938
    [TBL] [Abstract][Full Text] [Related]  

  • 16. HDAC inhibitors for the treatment of cancer.
    Secrist JP; Zhou X; Richon VM
    Curr Opin Investig Drugs; 2003 Dec; 4(12):1422-7. PubMed ID: 14763127
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Histone deacetylase inhibitors as novel anti-inflammatory agents.
    Adcock IM
    Curr Opin Investig Drugs; 2006 Nov; 7(11):966-73. PubMed ID: 17117583
    [TBL] [Abstract][Full Text] [Related]  

  • 18. FK228 (depsipeptide) as a natural prodrug that inhibits class I histone deacetylases.
    Furumai R; Matsuyama A; Kobashi N; Lee KH; Nishiyama M; Nakajima H; Tanaka A; Komatsu Y; Nishino N; Yoshida M; Horinouchi S
    Cancer Res; 2002 Sep; 62(17):4916-21. PubMed ID: 12208741
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Histone deacetylase inhibitor FK228 is a potent inducer of human fetal hemoglobin.
    Cao H; Stamatoyannopoulos G
    Am J Hematol; 2006 Dec; 81(12):981-3. PubMed ID: 16888791
    [TBL] [Abstract][Full Text] [Related]  

  • 20. FR901228, an inhibitor of histone deacetylases, increases the cellular responsiveness to IL-6 type cytokines by enhancing the expression of receptor proteins.
    Blanchard F; Kinzie E; Wang Y; Duplomb L; Godard A; Held WA; Asch BB; Baumann H
    Oncogene; 2002 Sep; 21(41):6264-77. PubMed ID: 12214267
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.